Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will participate in two investor conferences on November 29 and December 1, 2022. The conferences include the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference. Key executives, including CEO Lonnel Coats and CFO Jeffrey Wade, will engage in discussions at these events. Webcasts of the discussions will be accessible on Lexicon's website, with recordings available for two weeks post-event. Lexicon focuses on developing innovative medicines targeting various diseases.

THE WOODLANDS, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2022:

• 34^th Annual Piper Sandler Healthcare Conference
• 5^th Annual Evercore ISI HealthCONx Conference

Lonnel Coats, Lexicon’s chief executive officer, Jeffrey L. Wade, Lexicon’s president and chief financial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in moderated discussions at the Piper Sandler conference on Tuesday, November 29^th, at 11:00 am ET and at the Evercore ISI conference on Thursday, December 1^st at 8:00 am ET.

A simultaneous webcast of both discussions will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events, and a recording of the webcast will be available for two weeks following the original on-demand date.

About Lexicon Pharmaceuticals

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin, LX9211 and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, successfully commercialize any products for which it obtains regulatory approval, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For Investor Inquiries:

Carrie Siragusa
Lexicon Pharmaceuticals, Inc.
csiragusa@lexpharma.com 

For Media Inquiries:

Alina Kolomeyer
Lexicon Pharmaceuticals, Inc.
akolomeyer@lexpharma.com

FAQ

What dates is Lexicon Pharmaceuticals participating in investor conferences?

Lexicon Pharmaceuticals will participate in investor conferences on November 29 and December 1, 2022.

Which conferences will Lexicon Pharmaceuticals attend?

Lexicon Pharmaceuticals will attend the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference.

Who are the key executives participating in the conferences for Lexicon Pharmaceuticals?

Key executives include CEO Lonnel Coats, CFO Jeffrey Wade, and CMO Craig Granowitz.

When will the discussions from the Piper Sandler conference take place?

The discussion at the Piper Sandler conference is scheduled for Tuesday, November 29, 2022, at 11:00 am ET.

What time will Lexicon's executives speak at the Evercore ISI HealthCONx Conference?

Executives will participate in discussions at the Evercore ISI conference on Thursday, December 1, 2022, at 8:00 am ET.

Where can I watch the webcasts of Lexicon Pharmaceuticals' discussions?

Webcasts will be available in the 'Events' section of Lexicon's website.

How long will the recordings of the Lexicon Pharmaceuticals' webcasts be available?

Recordings of the webcasts will be available for two weeks after the original event.